Aurinia Pharmaceuticals Inc (AUPH)

[Lunacy_John Galt]

Hey Jess, there are examples of phase 3 double blind studies being stopped early by the independent Data Monitoring Committee (DMC) due to positive efficacy results. Personally, I think the chances for that are pretty low. What seems much more likely is that the company is acquired before the trial is completed. It’s also very possible that Auph’s management team might feel they let go of their previous company for too little $ in retrospect, so now they’re willing to take this one into commercialization to get maximum value...IMHO. I believe this is one of the reasons we saw a change at CEO before Ph2b results came out.